Takeda Pharmaceutical Co Ltd
TSE:4502
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 903
4 482
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Cost of Revenue
Takeda Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cost of Revenue
-¥1.5T
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-12%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cost of Revenue
-¥420B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cost of Revenue
-¥648.6B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Cost of Revenue
-¥59.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cost of Revenue
-¥337.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Cost of Revenue
-¥383.6B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
Takeda Pharmaceutical Co Ltd
Glance View
Takeda Pharmaceutical Co. Ltd. stands as a formidable player in the global healthcare landscape, firmly established as Japan's largest pharmaceutical company. Founded in 1781, Takeda has built a rich legacy of innovation and patient-centricity, evolving from a traditional medicine distributor into a leader in biopharmaceuticals. The company primarily focuses on therapeutic areas such as oncology, gastroenterology, neuroscience, and rare diseases, thus targeting critical health challenges faced by patients worldwide. Takeda's commitment to research and development, underscored by significant investments, facilitates the discovery of new treatments and the enhancement of existing therapies. This forward momentum is particularly noteworthy as it aligns with the growing demand for advanced medications and biologics, positioning Takeda favorably in a competitive market. In recent years, Takeda has strategically expanded its global footprint through key acquisitions, most notably the purchase of Shire in 2019, which significantly enhanced its portfolio in rare diseases. For investors, this positions Takeda not just as a pharmaceutical giant, but as an agile and innovative entity eager to meet the evolving needs of healthcare. With a robust pipeline that promises a mix of newly launched therapeutics and a focus on sustainable growth, Takeda showcases its resilience in navigating the pharmaceutical industry's challenges. The company's dedication to fostering partnerships, along with its ethical approach to business, further strengthens its reputation as a trustworthy investment in the pharmaceutical sector. For investors looking for a blend of historical stability and future potential in a company deeply committed to health and well-being, Takeda stands out as a compelling choice.
See Also
What is Takeda Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-1.5T
JPY
Based on the financial report for Sep 30, 2024, Takeda Pharmaceutical Co Ltd's Cost of Revenue amounts to -1.5T JPY.
What is Takeda Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-12%
Over the last year, the Cost of Revenue growth was -18%. The average annual Cost of Revenue growth rates for Takeda Pharmaceutical Co Ltd have been -15% over the past three years , -9% over the past five years , and -12% over the past ten years .
You don't have any saved screeners yet
